HDAC6 and T-cell acute lymphoblastic leukemia: In T-cell acute lymphoblastic leukemia (T-ALL), SUZ12 mutations activate oncogenic signaling pathways, increasing sensitivity to HDAC6 inhibitors (Broux et al., 2019).